Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1624 1626 4100
This examiner grants 85% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18122780 | BICYCLIC COMPOUND AND USE THEREOF | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18289047 | TREATING LIVER DISEASE | Final Rejection | Regents of the University of Minnesota |
| 18836800 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | Non-Final OA | Novartis AG |
| 17793204 | MULTICYCLIC CARBOCATION AND CARBORADICAL COMPOUNDS AND METHODS OF USE | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18546087 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | Final Rejection | Hoffmann-La Roche Inc. |
| 18592897 | HETEROCYCLIC COMPOUND AND USE THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18293171 | PHOTOACTIVATABLE PRODRUG NANOPARTICLES FOR COMBINED ANTI-ANGIOGENESIS AND PHOTODYNAMIC THERAPY | Non-Final OA | The University of Hong Kong |
| 18019771 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18683412 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | Non-Final OA | UCL BUSINESS LTD |
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy